Invitae

Komodo Grows Its MapEnhance Offering, Expanding Access to New Social Determinants of Health Insights Alongside Real-World Oncology Data and Rare Disease Genomics

Retrieved on: 
Montag, Mai 13, 2024
Other Health, Other Science, Pharmaceutical, Research, Artificial Intelligence, Oncology, Software, Professional Services, Genetics, Data Management, Science, Technology, Clinical Trials, FDA, General Health, Biotechnology, Data Analytics, Health, Health Technology, Partnership, Genomics, Patient, Data, Intelligence, COTA, News, Health information management, Neutropenia, Clinical trial, Disease, Mental health, AI, Hypertension, Cancer, Neurology, Drug discovery, SDOH, Medicine, Mitigation, Invitae, Mortality, GeneDx, Pharmaceutical industry

Today, Komodo Health announced a series of updates to its MapEnhanceTM offering, increasing the depth and volume of insights into social determinants of health (SDOH).

Key Points: 
  • Today, Komodo Health announced a series of updates to its MapEnhanceTM offering, increasing the depth and volume of insights into social determinants of health (SDOH).
  • “In a landscape where healthcare costs are skyrocketing, the demand for accurate, nuanced, and unbiased data has never been more critical,” said Brad Kelley, General Manager of MapEnhance, Komodo Health.
  • All MapEnhance data products come de-identified and ready to use, offering faster and timelier access to in-depth insights that can help to reduce the global burden of disease.
  • Komodo offers the industry’s most rigorous process for de-duplicating, normalizing, analyzing, and correcting the data that enters its Healthcare Map.

Paddi Hurley Joins Allison as Managing Director, Health Practice

Retrieved on: 
Montag, Dezember 11, 2023
Content Marketing, Other Communications, Public Relations, Investor Relations, Marketing, Communications, Other Health, Digital Marketing, Health, General Health, Invitae, Dexcom, Multimedia, Tourism

Allison announced health communications veteran Paddi Hurley has joined the firm as managing director, health.

Key Points: 
  • Allison announced health communications veteran Paddi Hurley has joined the firm as managing director, health.
  • Hurley brings more than 25 years of award-winning health experience, leading integrated communications programs across therapeutic areas and throughout the product lifecycle.
  • View the full release here: https://www.businesswire.com/news/home/20231206045754/en/
    “Hurley has a track record of successfully launching health portfolios with double digit growth,” said Scott Allison, global chairman and CEO of Allison.
  • Prior to joining Allison, Hurley launched the health portfolio at Twelvenote, the health and wellness agency of Lippe Taylor Group.

Hudson Pacific Appoints Robert Harris to Board of Directors

Retrieved on: 
Montag, November 13, 2023
Commercial Building & Real Estate, Construction & Property, REIT, NYSE, Recreation, Invitae, EPR Properties, AMC Theatres, Hudson Pacific Properties, Pepperdine University, Business, Acacia Research, AMC, Management

Hudson Pacific Properties, Inc. (NYSE: HPP), a unique provider of end-to-end real estate solutions for tech and media tenants, today announced that Robert “Chip” Harris II has been appointed to the company’s Board of Directors effective November 8, 2023.

Key Points: 
  • Hudson Pacific Properties, Inc. (NYSE: HPP), a unique provider of end-to-end real estate solutions for tech and media tenants, today announced that Robert “Chip” Harris II has been appointed to the company’s Board of Directors effective November 8, 2023.
  • Harris succeeds outgoing board member Karen Brodkin.
  • Prior to that, Harris founded and served as President of Entertainment Properties Trust, a publicly listed entertainment, recreation and specialty real estate company.
  • “We want to thank Karen for her service to Hudson Pacific, and we are pleased to welcome Chip back to our Board,” said Victor Coleman, Chairman and CEO.

Ciitizen Forges New Path as Independent Company

Retrieved on: 
Mittwoch, Dezember 13, 2023
Drug development, HIPAA, Genetics, SAN, Policy, StubHub, Patient, Algorithm, Heart, General partnership, Ecosystem, Caregiver, Stanford University, Houzz, Partnership, Emerge Commerce, Pharmaceutical industry, Invitae

SAN FRANCISCO, Dec. 13, 2023 /PRNewswire/ -- Ciitizen, the leading patient-directed healthcare platform, today announced its formation as an independent company following its divestiture announced by Invitae Corporation (NVTA). Ciitizen will continue with its mission to enable faster drug development and improve therapies and support for patients with rare and complex diseases. 

Key Points: 
  • Ciitizen will continue with its mission to enable faster drug development and improve therapies and support for patients with rare and complex diseases.
  • Using its proprietary AI models and algorithms, Ciitizen creates patient and disease profiles with unprecedented detail and personalization.
  • "Ciitizen's direct relationships with patients are at the heart of our platform," said Farid Vij, Chief Executive Officer of Ciitizen.
  • Ciitizen and Invitae intend to collaborate on key initiatives as the Ciitizen platform expands globally.

Invitae Appoints Dr. David Sholehvar as Chief Operating Officer

Retrieved on: 
Donnerstag, Oktober 19, 2023
Ortho Clinical Diagnostics, NYSE, Infection, RSU, University, Marketing, Employment, Quest Diagnostics, Business, Health, Johnson & Johnson, New York Stock Exchange, Thomas Jefferson University, SAN, Pharmaceutical industry, Management, Quest, Best Buy, Invitae

SAN FRANCISCO, Oct. 19, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D., as chief operating officer, effective November 13, 2023.

Key Points: 
  • SAN FRANCISCO, Oct. 19, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D., as chief operating officer, effective November 13, 2023.
  • "I'm excited to welcome Dr. Sholehvar to the Invitae leadership team.
  • His extensive general management experience in both large and small healthcare companies, as well as global functional leadership in sales, marketing, strategy and innovation will be an enormous benefit to Invitae as we continue our focus on operational excellence and innovation," said Ken Knight, president and chief executive officer of Invitae.
  • From 2017 to 2020, Dr. Sholehvar served as chief executive officer for Dynex Technologies, Inc., a manufacturer of laboratory instruments and associated consumables and accessories, where his focus was transforming Dynex's business model.

Vesica Health Announces the Appointment of Recognized Industry Leaders to Newly Formed Board of Directors

Retrieved on: 
Dienstag, Oktober 17, 2023
Quest Diagnostics, Breast cancer, Harvard University, HEALTH, Communications officer, USS, Liquid biopsy, Research, Quality of life, IVD, NL, USS Fletcher (DD-992), US, Swidler Berlin Shereff Friedman, National Institute for Public Health and the Environment, AkzoNobel, Invitae, Bladder cancer, Corporate development, PCR, Biotechnology, DE, FDA, Berlin, Ventana Medical Systems, Erasmus MC, Genomics, Morgan Stanley Wealth Management, Public health, Sale, International law, Vaccine, General counsel, RIVM, Hematuria, Labcorp, Independent, Duke University, Executive, Roche, Patient, Management, Vesica, EU

"It is with great pleasure that we announce the appointment of Dr. Jan Groen, Mark McDonough, and Joe Sollee to our Board of Directors.

Key Points: 
  • "It is with great pleasure that we announce the appointment of Dr. Jan Groen, Mark McDonough, and Joe Sollee to our Board of Directors.
  • "Based on my experience, Vesica has a singular opportunity to not only take market share but drive widespread clinical adoption of its AssureDx test."
  • "Vesica is uniquely positioned with an impressive portfolio of intellectual property issued both domestically and internationally," commented Joe Sollee.
  • "Speaking on behalf of my fellow Board members, we are excited to be joining Vesica's Board at this important time for the company.

Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics

Retrieved on: 
Dienstag, Oktober 10, 2023
Steps, National Society of Genetic Counselors, NYSE, Classification, Sibling, Breast cancer, Health, Genetic counseling, CGC, Gene, Phenotype, Research, AGS, Conference, Fiat 500X, NSGC, DNA, DSM-IV codes, Boston Children's Hospital, MPH, KCNQ2, Aicardi–Goutières syndrome, ACMG, Prostate cancer, National Society, RNA, Effectiveness, Risk, Cancer, Heart, Population genomics, University of Connecticut Health Center, SAN, End Stage Renal Disease Program, Senior counsel, Huntington's disease, Uncertainty, Family, LCGC, Genetic, VUS, UPMC Children's Hospital of Pittsburgh, Hospital, PMS2, Genetics, Patient, Genetic testing, HD, Outline of counseling, Pharmaceutical industry, Nursing, Communications satellite, Medical imaging, Birth control, Vaccine, Woman, Invitae

SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of Genetic Counselors (NSGC) 42nd Annual Conference in Chicago that highlights the importance of genetics-informed patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award which recognizes excellence in the field of genetic counseling.

Key Points: 
  • In addition to its research presentations, the company will present the Heart of Genetic Counseling Award which recognizes excellence in the field of genetic counseling.
  • "The NSGC Annual Conference is a great opportunity for Invitae researchers to share cutting-edge scientific advancements with genetic counselors who play an integral role in genetics-informed patient care," said Robert Nussbaum, M.D., chief medical officer at Invitae.
  • Invitae joins NSGC in presenting the Heart of Genetic Counseling Award – honoring excellence in genetic counseling and patient care as recognized by patients.
  • To learn more about Invitae's presence at the NSGC 42nd Annual Conference or the Heart of Genetic Counseling Award, visit our website .

Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization

Retrieved on: 
Dienstag, Oktober 3, 2023
FDA, Cancer, Patient, News, NYSE, Gene, SAN, Marketing, De novo, Common, Medical device, Invitae

SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel. This represents the first broad panel that is used to identify germline variants associated with hereditary cancer to gain market authorization from the FDA. The company believes that this is a strong vote of confidence in its Common Hereditary Cancers Panel, which has the potential to benefit patients, providers and payers.

Key Points: 
  • SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel.
  • This represents the first broad panel that is used to identify germline variants associated with hereditary cancer to gain market authorization from the FDA.
  • The company believes that this is a strong vote of confidence in its Common Hereditary Cancers Panel, which has the potential to benefit patients, providers and payers.
  • In 2021, the company submitted a de novo application using the Common Hereditary Cancers Panel as an example of a methods-based approach to validation.

Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

Retrieved on: 
Montag, September 25, 2023
New York Stock Exchange, Employment, Fordham University, College, RSU, McKesson Corporation, Head, MBA, Pharmacy, Accounting, Patient, SAN, CFO, Growth, NYSE, Management, Invitae

SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2.

Key Points: 
  • SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2.
  • "We're excited to welcome Ana to our Invitae team.
  • Most recently, Ms. Schrank served as CFO for Truepill, Inc., a digital health platform powering pharmacy experiences that patients interact with every day, where she led finance, accounting and human resources.
  • Ms. Schrank holds an MBA in finance from Fordham University and a BA in English literature from the College of William & Mary.

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

Retrieved on: 
Freitag, September 22, 2023
Acceleration, NYSE Listed Company Manual, NYSE, SAN, Pharmaceutical industry, Invitae

The NYSE notice has no immediate effect on the listing of the common stock on the NYSE, subject to the company's compliance with the NYSE's continued listing requirements.

Key Points: 
  • The NYSE notice has no immediate effect on the listing of the common stock on the NYSE, subject to the company's compliance with the NYSE's continued listing requirements.
  • Invitae has notified the NYSE that it intends to bring the company into compliance with the listing standards within the required cure period.
  • The NYSE notification described above does not affect the company's business operations and does not conflict with or cause an event of default or acceleration under any of the company's material debt or other agreements.
  • During the cure period, Invitae's common stock will continue to trade on the NYSE, subject to compliance with the other continued listing requirements.